Novel antibacterial agents for skin and skin structure infections

Journal of the American Academy of Dermatology

Volumn 50, Issue 3, 2004, Pages 331-340

  Schweiger, Eric S ^a   Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GATIFLOXACIN; LINEZOLID; MOXIFLOXACIN; ORITAVANCIN; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ATROPHY; BLEEDING; BURNING SENSATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HYPERSENSITIVITY; INFLAMMATION; INJECTION PAIN; LIVER DYSFUNCTION; MULTIDRUG RESISTANCE; MUSCLE DISEASE; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; SIDE EFFECT; SKIN INFECTION; THROMBOPHLEBITIS; VOMITING;

EID: 1542284069     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.10.665     Document Type: Note

References (53)

1. Centers for Disease Control. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-6.
2. Zyvox [package insert]. Kalamazoo, MI; Pharmacia & Upjohn Company; 2000.
3. Slee AM, Wuonola MA, McRipley RJ, Zajac I, Zawada MJ, Bartholomew PT, et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 1987;31:1791-7.
4. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5.
5. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745-7.
6. Ford CW, Hamel JC, Wilson DM, Moerman JK, Stapert D, Yancey RJ Jr, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996;40:1508-13.
7. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766, 2 novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1997;41:465-7.
8. Mercier RC, Penzak SR, Rybak MJ. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faeclum. Antimicrob Agents Chemother 1997;41:2573-5.
9. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059-62.
10. Clemett D, Markham A. Linezolid. Drugs 2000;59:815-27.
11. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001;61:525-51.
12. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-13.
13. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B, Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
14. Batts DH. Linezolid-a new option for treating gram-positive infections. Oncology (Huntingt) 2000;14(Suppl 6):23-9.
15. Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003;185:369-75.
16. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002;50:743-6.
17. Barrett JF. Linezolid Pharmacia Corp. Curr Opin Investig Drugs 2000;1:181-7.
18. Bryson HM, Spencer CM. Quinupristin-dalfopristin: antibacterial activity, pharmokinetic profile, therapeutic trials, tolerability and current status. Drugs 1996;52:406-15.
19. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997;39(Suppl A):7-13.
20. Lamb HM, Figgitt DP, Faulds D. Quinuprastin/dalfopristin. A review of its use in the management of serious gram-positive infections. Drugs 1999;58:1061-97.
21. Landman D, Quale JM. Management of infections due to resistant enterococci: a review of therapeutic options. J Antimicrob Chemother 1997;40:161-70.
22. Linden PK, Pasculle AW, McDevitt D. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A):145-51.
23. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44:263-73.
24. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161:753-62.
25. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44:251-61.
26. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001;32:e83-6.
27. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999;44(Suppl A):37-46.
28. Stamatakis MK, Richards JG. Interaction between quinupristin/ dalfopristin and cyclosporine. Ann Pharmacother 1997;31:576-8.
29. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473-81.
30. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs 2003;12:379-99.
31. Wesson KM, Lerner DS, Silverberg NB, Weinberg JM. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Clin Dermatol 2003;21:64-70.
32. Canepari P, Boaretti M, del Mar Lleo M, Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 1990;34:1220-6.
33. Boaretti M, Canepari P, Lieo MM, Satta G. The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J Antimicrob Chemother 1993;31:227-35.
34. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:2282-7.
35. Allen NE, Alborn WE Jr, Hobbs JN Jr. Identification of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 1991;35:2639-42.
36. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36:318-25.
37. Garrison MW, Vance-Bryan K, Larson TA, Toscano JP, Rotschafer JC. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1990;34:1925-31.
38. Ryback MJ, Bailey EM, Lamp KC, Kaatz GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992;36:1109-14.
39. Tally FP, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for gram-positive infections. Expert Opin Investig Drugs 1999;8:1223-38.
40. Ryback MJ, Hershberger E, Moldovan T, Gruez RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains. Antimicrob Agents Chemother 2000;44:1062-6.
41. Stephenson J. Researchers describe latest strategies to combat antibiotic-resistant microbes. JAMA 2001;285:2317-8.
42. Strahilevitz J, Rubinstein E. Novel agents for resistant gram-positive infections-a review. Int J Infect Dis 2002;6(Suppl 1):S38-46.
43. Cubicin [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2003.
44. Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 1991;35:1710-6.
45. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003;26:511-32.
46. Barrett JF. Oritavancin. Eli Lilly & Co. Curr Opin Investig Drugs 2001;2:1039-44.
47. Mercier RC, Stumpo C, Rybak MJ. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother 2002;50:19-24.
48. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998;42:981-3.
49. Woodford N. Novel agents for the treatment of resistant gram-positive infections. Expert Opin Investig Drugs 2003;12:117-37.
50. Steiert M, Schmitz FJ. Dalbavancin (Biosearch Italia/Versicor). Curr Opin Investig Drugs 2002;3:229-33.
51. Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother 2001;45:2358-62.
52. Parish LC, Routh HB, Miskin B, Fidelholtz J, Werschler P, Heyd A, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000;54:497-503.
53. Muijsers R, Jarvis B. Moxifloxacin: in uncomplicated skin and skin structure infections. Drugs 2002;62:967-73.